ZKB/CALL/MODERNA/125/0.025/27.01.25 | Market Closed - Swiss Exchange 08:50:00 14/06/2024 pm IST | ||
| 0.79 CHF | -9.20% |
|
| Current month | -14.13% | ||
| 1 month | +31.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 0.79 | -9.20% |
| 12/24/12 | 0.87 | -4.40% |
| 11/24/11 | 0.91 | +3.41% |
| 10/24/10 | 0.88 | -10.20% |
| 07/24/07 | 0.98 | -7.55% |
Delayed Quote Swiss Exchange
Last update June 14, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | ZKB |
| MRNFQZ | |
| ISIN | CH1305130945 |
| Date issued | 22/01/2024 |
| Strike | 125 $ |
| Maturity | 27/01/2025 (225 Days) |
| Parity | 40 : 1 |
| Emission price | 0.39 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.29 CHF |
|---|---|
| Lowest since issue | 0.2 CHF |
| Spread | 0.01 CHF |
| Spread % | 1.27% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Warrants
- MRNFQZ Warrant
